Meta-analysis of c-Myc gene expression in prognosis of elderly patients with NSCLC underwent surgery and chemoradiotherapy

Guo, Z.L.

doi:10.61186/ijrr.23.2.31

[Home ] [Archive]

International Journal of Radiation Research

Main Menu

Home

IJRR Information

For Authors

For Reviewers

Subscription

News & Events

Web Mail

Search in website

Receive site information

ISSN

Hard Copy 2322-3243

Online 2345-4229

Online Submission

Now you can send your articles to IJRR office using the article submission system.

Volume 23, Issue 2 (5-2025) Int J Radiat Res 2025, 23(2): 481-487 | Back to browse issues page

‎ 10.61186/ijrr.23.2.31

Mendeley

Zotero

RefWorks

Guo Z. Meta-analysis of c-Myc gene expression in prognosis of elderly patients with NSCLC underwent surgery and chemoradiotherapy. Int J Radiat Res 2025; 23 (2) :481-487
URL: http://ijrr.com/article-1-6433-en.html

Meta-analysis of c-Myc gene expression in prognosis of elderly patients with NSCLC underwent surgery and chemoradiotherapy

Z.L. Guo

Department of Geriatrics, Zhuji People's Hospital, Zhuji, China , guo198210062023@163.com

Abstract: (544 Views)

Background: This paper is conducted to analysis the effects of c-Myc gene expression on surgical intervention and outlook of elderly sufferers with Non-Small Cell Lung Cancer (NSCLC) through meta-analysis. Materials and Methods: Through searching the key words "small cell lung cancer, c-Myc" on China National Knowledge Internet (CNKI) and other platforms, the literature meeting the inclusion criteria was screened. Finally, a total of 14 relevant studies were included. Statistical methods were used to analyze the data, including calculation of standard deviation and 95% confidence interval, and for analysis, the fixed effects model was utilized. Results: Meta-analysis of untreated and healthy groups showed that serum c-Myc mRNA expression in untreated group is remarkably superior to healthy group (standard deviation -1.64, 95% confidence interval -1.85 to -1.45, P<0.001). In addition, serum c-Myc mRNA expression levels in elderly sufferers with NSCLC are remarkably superior to younger group (standard deviation 1.45, 95% confidence interval 1.15 to 1.74, P<0.001). In addition, serum c-Myc mRNA expression in the non-smoking group is remarkably superior to smoking group (OR=-1.78, 95% CI -1.95 to -1.60, P<0.001). Conclusions: Serum c-Myc mRNA expression levels in elderly NSCLC suffers are superior to healthy groups, which were related to age and smoking behavior. This finding is significant for the early screening, diagnosis and prognosis assessment of NSCLC, providing a basis for further research on the role of c-Myc gene in elderly NSCLC.

Keywords: C-Myc gene expression, non-small cell lung cancer, chemoradiotherapy, meta-analysis.

Full-Text [PDF 662 kb] (162 Downloads)

Type of Study: Review article | Subject: Radiation Biology

References

1. 1. Wang M, Herbst RS, Boshoff C (2021) Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine, 27(8): 1345-1356. [DOI:10.1038/s41591-021-01450-2]

2. Stamatelopoulos A, Kadjianis F, Zoganas L (2009) Non small cell lung cancer: surgical treatment in the elderly.. Journal of B.U.ON., 14(3): 381-389.

3. Alexander M, Kim SY, Cheng H (2020) Update 2020: management of non-small cell lung cancer. Lung, 198: 897-907. [DOI:10.1007/s00408-020-00407-5]

4. Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. Journal of Clinical Oncology, 40(6): 586-597. [DOI:10.1200/JCO.21.01497]

5. Mimae T, Miyata Y, Tsutani Y, et al. (2020) Wedge resection as an alternative treatment for octogenarian and older patients with early-stage non-small-cell lung cancer. Japanese Journal of Clinical Oncology, 50(9): 1051-1057. [DOI:10.1093/jjco/hyaa085]

6. de Ruiter JC, Heineman DJ, Daniels JMA, et al. (2020) The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands. Lung Cancer, 144: 64-70. [DOI:10.1016/j.lungcan.2020.04.005]

7. Tantraworasin A, Siwachat S, Tanatip N, et al. (2020) Outcomes of pulmonary resection in non-small cell lung cancer patients older than 70 years old. Asian Journal of Surgery, 43(1): 154-165. [DOI:10.1016/j.asjsur.2019.03.006]

8. Jänne PA, Riely GJ, Gadgeel SM, et al. (2022) Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. New England Journal of Medicine, 387(2): 120-131. [DOI:10.1056/NEJMoa2204619]

9. Li BT, Smit EF, Goto Y, et al. (2022) Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. New England Journal of Medicine, 386(3): 241-251. [DOI:10.1056/NEJMoa2112431]

10. Drilon A, Oxnard GR, Tan DSW, et al. (2020) Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. New England Journal of Medicine, 383(9): 813-824. [DOI:10.1056/NEJMoa2005653]

11. Patrapim S, Patcharaporn T, Rassamee C, Surasak S, Paramee T (2022) Copy number gains of chromosome 17 identified by dual in situ hybridization in non-small cell lung cancer tissue correlate with overexpression of c-Myc.. Translational Cancer Research, 11(5): 1033-1044. [DOI:10.21037/tcr-21-2705]

12. Ren X, Yu J, Guo L, et al. (2021) Circular RNA circRHOT1 contributes to pathogenesis of non-small cell lung cancer by epigenetically enhancing C-MYC expression through recruiting KAT5. Aging (Albany NY), 13(16): 20372-20382. [DOI:10.18632/aging.203417]

13. Li W, Li C, Ma L, et al. (2020) Resveratrol inhibits viability and induces apoptosis in the small-cell lung cancer H446 cell line via the PI3K/Akt/c-Myc pathway. Oncology Reports, 44(5): 1821-1830. [DOI:10.3892/or.2020.7747]

14. Zhang Q, Zhang Y, Chen H, Sun LN, Zhang B, Yue DS, Wang Chang Li, Zhang Zhen Fa (2022) METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m;6;A/c-Myc-dependent aerobic glycolysis. Cell Cycle, 21(24): 2602-2614. [DOI:10.1080/15384101.2022.2105885]

15. Wang Z, Huang Y, Lu W, Liu J, Li X, Zhu Sa, Liu H, Song Y (2022) C-myc-mediated upregulation of NAT10 facilitates tumor development via cell cycle regulation in non-small cell lung cancer. Medical Oncology, 39(10): 140. [DOI:10.1007/s12032-022-01736-6]

16. Chen H, Jia B, Zhang Q, Zhang Y (2022) Meclofenamic acid restores Gefinitib sensitivity by downregulating breast cancer resistance protein and multidrug resistance protein 7 via FTO/m6A-Demethylation/c-Myc in non-small cell lung cancer . Frontiers in Oncology, 12: 870636. [DOI:10.3389/fonc.2022.870636]

17. Zhang Y, Wang Y, Li Ya, Huang C, Xiao X, Zhong Z, et al. (2022) Dihydroartemisinin and Artesunate Inhibit Aerobic Glycolysis via Suppressing c-Myc Signaling in non-small Cell Lung Cancer. Biochemical Pharmacology, 198: 114941. [DOI:10.1016/j.bcp.2022.114941]

18. Tu Y, Yao S, Chen Q, Li W, Song Y, Zhang P (2022) 5-Hydroxytryptamine activates a 5-HT/c-Myc/SLC6A4 signaling loop in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - General Subjects, 1866(4):130093. [DOI:10.1016/j.bbagen.2022.130093]

19. Patrapim S, Patcharaporn T, Rassamee C, Surasak S, Paramee T (2023) Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 among patients with non-small cell lung cancer. Clinical Medicine Insights. Oncology, 16: 47. [DOI:10.1177/11795549221092747]

20. Altorki N, Wang X, Kozono D, et al. (2023) Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. New England Journal of Medicine, 388(6): 489-498. [DOI:10.1056/NEJMoa2212083]

21. Ettinger DS, Wood DE, Aisner DL, et al. (2022) Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20(5): 497-530.

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Persian site map - English site map - Created in 0.04 seconds with 50 queries by YEKTAWEB 4722